An in vitro pharmacodynamic spiking study of befovacimab, a tissue factor pathway inhibitor monoclonal antibody, in blood samples from patients with severe FVIII deficiencyHAEMOPHILIAIF32021-04-293PREAI
Marstacimab, a tissue factor pathway inhibitor neutralizing antibody, improves coagulation parameters of ex vivo dosed haemophilic blood and plasmasHAEMOPHILIAIF32019-07-2335PREAI
Use of global assays to monitor emicizumab prophylactic therapy in patients with haemophilia A with inhibitorsHAEMOPHILIAIF32019-02-1213PREAI
Evaluating the thrombin generation profiles of four different rFVIII products in FVIII-deficient plasma using FXIa and FXIa activationHAEMOPHILIAIF32018-08-166PREAI
Successful multi-modal immune tolerance induction for factor IX deficiency with inhibitors and allergic reactionsHAEMOPHILIAIF32018-03-303PREAI
Modulation of the activated protein C pathway in severe haemophilia A patients: The effects of thrombomodulin and afactor V-stabilizing fabHAEMOPHILIAIF32017-07-271PREAI
Coated platelets and severe haemophilia A bleeding phenotype: Is there a connection?HAEMOPHILIAIF32015-11-116PREAI
Monitoring rFVIIa 90 μg kg-1 dosing in haemophiliacs: comparing laboratory response using various whole blood assays over 6 hHAEMOPHILIAIF32011-03-0118PREAI
Effect of recombinant factor VIIa variant (NN1731) on platelet function, clot structure and force onset time in whole blood from healthy volunteers and haemophilia patientsHAEMOPHILIAIF32007-07-2025PREAI
Percutaneous liver biopsy in adult haemophiliacs with hepatitis C virus: safety of outpatient procedure and impact of human immunodeficiency virus coinfection on the spectrum of liver diseaseHAEMOPHILIAIF32007-01-2913OAAI